DuPont planning to sell its Medical Products businesses.
This article was originally published in The Gray Sheet
DUPONT $535 MIL. X-RAY AND IMAGING BUSINESS FOR SALE through J.P. Morgan & Co. as part of DuPont's May 19 announced plan to exit the medical products sector. The x-ray/imaging business, with an estimated 3,000 employees, is the largest of four components which are being put up for sale. The other units being divested are In-vitro Diagnostics ($335 mil.); New England Nuclear research products ($110 mil.); and Sorvall Centrifuges ($75 mil.).
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.